PACB - 10% Short Interest In Pacific Biosciences Makes Sense

• Pacific Biosciences of California, Inc. has raised a significant amount of cash through debt and share issuance in the last two years.
• The company continues to burn through cash and there seems to be no end in site despite recent revenue growth.
• Oxford Nanopore Technologies and other competitors are starting to encroach on PacBio's niche in the long-read sequencing space.
• There was a ~10% short position in the company at the end of October.
• Alternative names in the life science space offer a more compelling investment thesis.

For further details see: